Profile Response Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
NTRK1 fusion	Advanced Solid Tumor	sensitive	Larotrectinib	Clinical Study - Cohort	Actionable	In a combined analysis of three trials, Vitrakvi (larotrectinib) resulted in improved median overall survival (39.7 vs 10.2 months) and a 78% lower risk of death (HR=0.22, P=0.001) compared to standard of care treatment in patients with advanced solid tumors harboring NTRK fusions (PMID: 36689698; NCT02122913, NCT02637687, and NCT02576431).	36689698
NTRK1 fusion	Advanced Solid Tumor	sensitive	Larotrectinib	FDA approved	Actionable	In three trials that supported FDA approval, Vitrakvi (larotrectinib) treatment resulted in an overall response rate of 75% (41/55) in adult and pediatric patients with advanced solid tumors harboring either an NTRK1, NTRK2, or NTRK3 fusion, including 7 patients achieving a complete response and 34 patients achieving a partial response (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).	detail... 29466156 detail...
NTRK1 fusion	Advanced Solid Tumor	sensitive	Larotrectinib	Phase Ib/II	Actionable	In a Phase I/II trial (SCOUT), Vitrakvi (larotrectinib) treatment resulted in complete response in 26.7% (4/15), partial response in 66.7% (10/15), and stable disease in 6.7% (1/15) of pediatric patients with advanced solid tumors harboring NTRK fusions, and progressive diseases in all 7 patients without NTRK fusions (PMID: 29606586; NCT02637687).	29606586

PubMed Id	Reference Title	Details
	Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions	Full reference...
(29466156)	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.	Full reference...
(29606586)	Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.	Full reference...
	Vitrakvi (larotrectinib) FDA Drug Label	Full reference...
(36689698)	Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data.	Full reference...